Objectives: Soluble suppression of tumorigenicity-2 is a biomarker of myocardial strain and inflammation. The characteristics of acute respiratory distress syndrome include inflammation and cardiovascular dysfunction. We sought to determine whether plasma soluble suppression of tumorigenicity-2 concentration is associated with outcome and response to conservative fluid management and whether soluble suppression of tumorigenicity-2 concentration discriminates acute respiratory distress syndrome from decompensated heart failure.
Objectives: Soluble suppression of tumorigenicity-2 is a biomarker of myocardial strain and inflammation. The characteristics of acute respiratory distress syndrome include inflammation and cardiovascular dysfunction. We sought to determine whether plasma soluble suppression of tumorigenicity-2 concentration is associated with outcome and response to conservative fluid management and whether soluble suppression of tumorigenicity-2 concentration discriminates acute respiratory distress syndrome from decompensated heart failure.
Design: A retrospective analysis of the Fluid and Catheter Treatment Trial, a multi-center randomized controlled trial of conservative fluid management in the acute respiratory distress syndrome, as well as of a cohort of patients with decompensated heart failure. Setting: Twenty acute care hospitals. Patients: Eight hundred twenty-six patients with acute respiratory distress syndrome and 209 patients with acutely decompensated heart failure. Measurements and Main Results: Nonsurvivors had higher day 0 (p < 0.0001) and day 3 (p < 0.0001) soluble suppression of tumorigenicity-2 concentrations. After adjustment for severity of illness, higher soluble suppression of tumorigenicity-2 concentration was associated with mortality, with odds ratio adj 1.47 (95% CI, 0.99-2.20; p = 0.06) at day 0, 2.94 (95% CI, 2.00-4.33; p < 0.0001) at day 3, and 3.63 (95% CI, 2.38-5.53; p < 0.0001) if soluble suppression of tumorigenicity-2 increased between days. Cumulative fluid balance was more positive among patients with higher day 0 (median, 5,212 mL [interquartile range, 200-12,284 mL] vs median, 2,020 mL [interquartile range, -2,034 to 7,091 mL]; p < 0.0001) and day 3 soluble suppression of tumorigenicity-2 (median, 7,678 mL [interquartile range, 2,217-14,278 mL] vs median, 1,492 mL [interquartile range, -2,384 to 6,239 mL]; p < 0.0001). Soluble suppression of tumorigenicity-2 showed excellent discriminative ability between the Fluid and Catheter Treatment Trial and heart failure populations (area under receiver-operating characteristic curve = 0.98; p < 0.0001). Conclusions: Higher soluble suppression of tumorigenicity-2 concentrations are associated with worse outcome in acute respiratory distress syndrome and may have value for discriminating acute respiratory distress syndrome from heart failure. (Crit Care Med 2013; 41:2521-2531) Key Words: acute respiratory distress syndrome; biomarkers; fluid therapy A cute respiratory distress syndrome (ARDS) is a syndrome of respiratory failure characterized by systemic and pulmonary inflammation and endothelial injury resulting Dr. Harris is a board member at Altor Biosciences, has given expert testimony for MedQuest, received payment for the development of educational presentations from the American Physician Institute, and received grant support from NIH. Dr. Matthay has consulted for GSK, Biogen, and Roche Genentech; received grant support from NIHLBI, and received support for article research from NIH. Dr. Januzzi is a board member and has consulted for and received grant support from Critical Diagnostics. Dr. Thompson received grant support from NIHLBI. Dr. Bajwa received grant support from NIH. The remaining authors have disclosed that they do not have any potential conflicts of interest. in capillary leak, alveolar edema, and hypoxemia (1) . Pulmonary vascular dysfunction may result in myocardial injury and dysfunction (2) . ARDS is heterogeneous in etiology and progression and clinical data are often insufficient to guide therapy (3) . Studies have shown that biomarkers of inflammation (4, 5) and myocardial cell injury (6) are associated with prognosis in ARDS.
Suppression of tumorigenicity-2 (ST2) is an interleukin (IL)-1 receptor family member that exists in both a transmembrane and a soluble ST2 (sST2) isoform (7) . IL-33 is the functional ligand for ST2, and ST2/IL-33 signaling was first described as a mediator of inflammation and immunity (8) . In experiments using murine alveolar cell lines, inflammatory stimuli increased endogenous ST2 production, whereas pretreatment with sST2 significantly reduced cytokine production (9) . Other studies have shown that serum sST2 concentrations are elevated in patients with disorders, including asthma, idiopathic pulmonary fibrosis, severe sepsis, and trauma (10) (11) (12) . A study by Hoogerwerf et al (13) showed that sST2 concentrations were associated with disease severity and mortality in severe sepsis. These data suggest that sST2 could be associated with acute lung inflammation.
Other studies have suggested a role for ST2 in cardiac disease. Isolated cardiomyocytes exposed to mechanical strain up-regulate ST2 expression (14) . In animal models, ST2 pathway abnormalities are associated with myocardial fibrosis and dysfunction and reduced survival (15) . These studies are reinforced by clinical data showing that among patients with acute myocardial infarction, elevated sST2 concentrations are associated with increased risk of heart failure (HF) or mortality (16) , whereas in patients with HF, sST2 concentrations are among the most powerful biomarker predictors of death or hospitalization (17) .
Given these associations between ST2, inflammation, and myocardial strain, we hypothesized that sST2 concentrations would be associated with clinical outcomes in ARDS, a syndrome that combines elements of pulmonary inflammation and myocardial dysfunction. Given that sST2 is increased in conditions of cardiomyocyte stretch, we also sought to evaluate whether sST2 concentration was associated with response to treatment with different fluid management strategies. Finally, we sought to compare sST2 concentrations from ARDS patients to patients with myocardial strain due to acutely decompensated HF. We used samples from the Fluid and Catheter Treatment Trial (FACTT), a randomized controlled trial of liberal versus conservative fluid management in patients with ARDS (18) , and the N-terminal Pro-BNP Investigation of Dyspnea in the Emergency Department (PRIDE), an observational study of emergency department patients presenting with respiratory distress (19) .
MATERIALS AND METHODS

Study Design
Patients with ARDS, at that time referred to as "acute lung injury" prior to publication of the Berlin criteria (20) , were taken from FACTT (18) . This study demonstrated significant associations between conservative fluid management and the outcomes of ventilator-free days (VFD) and ICU-free days (IFD). All FACTT patients with available blood samples were included in our study. PRIDE was a prospective study of patients with acute respiratory distress, evaluating the utility of natriuretic peptide testing for HF diagnosis. We selected PRIDE subjects adjudicated to have acutely decompensated HF (n = 209). Complete FACTT and PRIDE protocols are as previously described (18, 19) , including inclusion and exclusion criteria. FACTT exclusion criteria (18) included presence of ARDS for more than 48 hours, inability to obtain consent, or presence of chronic or irreversible conditions influencing survival (such as advanced cancer), impairing weaning, or compromising protocol compliance (e.g., dialysis dependence). PRIDE exclusion criteria (19) included myocardial ischemia, severe chronic kidney disease, unblinded natriuretic peptide measurement, or prolonged interval between diuretic treatment and enrollment.
We used blood samples taken from FACTT patients on day 0 (the day of study enrollment) and day 3 (72 hr later) and PRIDE samples from day 0 (emergency department presentation). All studies were approved by institutional review boards.
Data Collection
FACTT baseline data included demographic characteristics, coexisting conditions, cause of ARDS, and Acute Physiology and Chronic Health Evaluation (APACHE) III score (21) . Physiologic variables were collected by study protocol. Outcomes included 60-day mortality, VFD, and IFD from hospital day 1 to 28. Other data included daily cumulative fluid balance, renal function variables, and presence of shock. PRIDE data included baseline characteristics, chest radiograph interpretation, and adjudicated etiology of respiratory distress. Acute kidney injury (AKI) was defined according to Acute Kidney Injury Network stage 1 criteria (22), as 50% or 0.3 mg/dL increase in serum creatinine from study days 0 to 3.
Blood Sample Analysis
Samples from both studies were stored in EDTA plasma at -80°C and assayed using a highly sensitive sST2 assay (Presage, Critical Diagnostics, San Diego, CA) (23).
Statistical Analysis
Data were analyzed using SAS v9.3 software (SAS Institute, Cary, NC). Categorical variables were compared using chisquare tests. Continuous variables were compared using Wilcoxon rank-sum tests. Receiver-operating characteristic (ROC) analysis was used to analyze the relationship between sST2 and mortality, and a cutpoint for mortality prediction was selected using the Youden (24) method. This cutpoint was used to stratify patients into groups by lower or higher sST2 concentration. Multivariate logistic regression was used to study the association between sST2 and 60-day mortality, adjusted for admission APACHE III score. Linear regression was used to study the association between day 0 sST2, fluid balance, and other covariates (shock, kidney injury, diuretic dose, and therapeutic strategy). 
RESULTS
Baseline Characteristics in FACTT
FACTT enrollment occurred as previously published (18) . Paired day 0/day 3 specimens were available from 826 patients. Patients from liberal and conservative treatment strategy groups had similar baseline characteristics ( Table 1) .
Characteristics of ST2 Concentrations
Day 0 and day 3 sST2 concentrations were significantly higher in nonsurvivors than survivors ( Fig. 1) . Day 0 median sST2 concentration was 517 ng/mL (interquartile range [IQR], 300-684 ng/mL) in survivors versus 590 ng/mL (IQR, 463-947 ng/ mL) in nonsurvivors (p < 0.0001). Day 3 median sST2 concentration was 250 ng/mL (IQR, 139-460 ng/mL) in survivors versus 495 ng/mL (IQR, 304-636 ng/mL) in nonsurvivors (p < 0.0001). The change in sST2 (day 3 concentration -day 0 concentration) was significantly different between survivors (median Δ, -210 ng/mL; IQR, -413 to -53 ng/mL) and nonsurvivors (median Δ, -104 ng/mL; IQR, -336 to -34 ng/mL; p < 0.0001). For patients whose sST2 concentration rose between days (n = 138), mortality was significantly higher (46% vs 19% for other patients, p < 0.0001).
Major Outcomes
We studied the relationship between sST2 and 60-day mortality using logistic regression ( Table 2) . ROC analysis was used to select cutpoints for separating patients into high and low sST2 groups at day 0 and day 3. The day 0 sST2 ROC cutpoint was 534 ng/mL and the day 3 ROC cutpoint was 296 ng/mL. Both day 0 and day 3 sST2 concentrations above the respective cutpoints, as well as increasing sST2 concentration between day 0 and day 3, were significantly associated with increased odds of death. We adjusted for severity of illness by adding baseline APACHE III score as a covariate to each model. Day 3 sST2 concentration above the ROC cutpoint and increasing sST2 concentration between day 0 and day 3 continued to be associated with increased odds of death after adjustment. Higher day 0 sST2 concentration was not significantly associated with mortality in the adjusted model. Testing for collinearity showed that both day 0 and day 3 concentrations were significantly correlated with APACHE III (R = 0.40, p < 0.0001 for day 0 and R = 0.42, p < 0.0001 for day 3). Change in sST2 concentration was not correlated with APACHE III (R = -0.06, p = 0.09).
Higher sST2 concentrations at day 0 and day 3 were independently associated with fewer VFD and IFD in the first 28 days of hospitalization. Increasing sST2 concentration between days 0 and 3 was also associated with decreases in both measures ( Table 3) .
Effect of Randomized Fluid Management Strategy on sST2 Concentration
Prior to initiation of fluid management, baseline sST2 concentrations were similar in both treatment groups (median, 540 ng/mL [IQR, 348-763 ng/mL] in liberal group vs median, 526 ng/mL [IQR, 306-713 ng/mL] in conservative group; p = 0.15). After therapy initiation, the change in concentration between day 0 and day 3 did not significantly differ between groups (median Δ, -182 ng/mL [IQR, -395 to -36 ng/mL] in liberal group vs median Δ, -186 ng/mL [IQR, -388 to -37 ng/ mL] in conservative group; p = 0.86). We then examined the group of patients who responded to protocol-directed therapy (as measured by successful reduction in central venous pressure [CVP] between days 0 and 3). These "responders" had higher ; p < 0.0001). In the conservative fluid management group, this group of patients whose CVP dropped had significantly greater reduction in sST2 (median Δ, -208 ng/mL; IQR, -389 to -48 ng/mL; p = 0.03), whereas sST2 concentrations did not decrease significantly among the corresponding group of patients whose CVP declined in the liberal management group (median Δ, -186 ng/mL; IQR, -378 to -46 ng/mL; p = 0.64). These associations remained significant even after excluding patients with shock (p = 0.05 in conservative group and p = 0.73 in liberal group). The proportion of patients developing AKI was also similar between "responder" groups (30% vs 27%, p = 0.49).
To explore these findings, we studied cumulative fluid balance between days 0 and 3. Fluid balance was significantly more positive among patients with higher day 0 sST2 (median, 5,212 mL [IQR, 200-12,284 mL] vs median, 2,020 mL [IQR, -2,034 to 7,091 mL]; p < 0.0001) and day 3 sST2 (median, 7,678 mL [IQR, 2,217-14,278 mL] vs median, 1,492 mL [IQR, -2,384 to 6,239 mL]; p < 0.0001). Because FACTT protocols required shock resolution prior to initiating treatment strategies, we performed subgroup analyses of patients who were not in shock at any point through day 3 (n = 415). Among nonshock patients, higher sST2 was associated with more positive fluid balance, median 1,847 mL (IQR, -1,695 to 7,131 mL) among higher day 0 sST2 patients versus 64 mL (IQR, -3,480 to 3,570 mL) among low day 0 sST2 patients (p = 0.001), and median 2,753 mL (IQR, -1,340 to 7,565 mL) for high day 3 sST2 patients versus median 206 mL (IQR, -3,158 to 3,574 mL) for low day 3 sST2 patients (p < 0.0001). We then compared fluid balance between fluid management groups with and without shock. Full results of these analyses are shown in Figure 2 , representing median fluid balances compared between fluid management and shock categories (data available in Supplemental Table 1 , Supplemental Digital Content 1, http://links.lww.com/CCM/ A687). For every combination of shock status and treatment group, fluid balance was more positive among patients with higher sST2, and in most cases this was statistically significant. Patients with higher day 3 sST2 had significantly more positive fluid balance for all shock categories regardless of treatment group.
To understand how day 3 sST2 concentration varied according to factors occurring on days 0 through 3, we conducted linear regression with day 3 sST2 concentration as the outcome and other factors as explanatory variables ( Table 4 ). In this model, baseline sST2 concentration, fluid balance, severity of illness, and development of AKI all had significant effects on day 3 sST2. Supplemental Table 2 (Supplemental Digital Content 1, http://links.lww.com/CCM/A687). FACTT patients were younger and more likely to have HIV infection. PRIDE patients were more likely to be diabetic or to have malignancies. Although APACHE score data were not available from PRIDE, there were small but statistically significant differences in serum blood urea nitrogen, creatinine, bicarbonate, glucose, and hematocrit (all higher in PRIDE).
Diagnostic Significance of Day 0 sST2 Concentration Baseline characteristics of PRIDE and FACTT populations are compared in
Baseline sST2 concentrations were significantly lower in PRIDE than FACTT (median, 534 ng/mL [IQR, 325.0-724.9 ng/ mL] vs median, 43 ng/mL [IQR, 26.4-78.6 ng/mL]; p < 0.0001). Among PRIDE patients with radiographic evidence of pulmonary edema (n = 87), median sST2 concentrations were 46 ng/ mL (IQR, 28.4-70.3 ng/mL), significantly lower than FACTT patients (p < 0.0001) (Fig. 3) . ROC analysis (Fig. 4) demonstrated area under the ROC curve of 0.98 (p < 0.0001), and an sST2 cutoff of 142 ng/mL was 91% sensitive and 94% specific for discriminating FACTT and PRIDE patients, with positive predictive value of 99%. In logistic regression, sST2 concentration above 142 ng/mL was associated with odds ratio of 191.4 for the diagnosis of ARDS (95% CI, 83.6-438.1; p < 0.0001).
DISCUSSION
Higher plasma sST2 concentration in ARDS was associated with unfavorable outcomes: increased duration of mechanical ventilation, longer ICU, and increased mortality. Plasma sST2 was also closely related to fluid balance, a relationship that persisted when accounting for shock, AKI, and diuretic dose. Interestingly, FACTT patients with ARDS had markedly higher sST2 concentrations than PRIDE patients with acutely decompensated HF, such that baseline sST2 concentrations were highly discriminative between these groups.
Higher sST2 concentrations on days 0 and 3 were associated with worse outcomes, and at both time points, sST2 concentration was correlated with baseline APACHE III score. Of Odds ratio for 60-day mortality associated with day 3 sST2 concentration above the ROC cutpoint. c Odds ratio for 60-day mortality associated with increase in sST2 concentration between day 0 and day 3. note, increasing sST2 concentration between days 0 and 3 was associated with markedly increased mortality risk, suggesting that changes in sST2 over time might provide information regarding changes in clinical condition. As sST2 is known to be involved in conditions of inflammation and myocardial strain (11, 12, 16) , it is not clear whether elevated concentrations are related to the presence of either process or to other aspects of ARDS pathophysiology. We found no evidence that randomization to conservative fluid management lowered sST2 concentrations. However, among patients whose CVP decreased when treated accordingly, sST2 decreased, whereas the same was not true for patients treated with liberal fluid management. Fluid management protocols were targeted toward reducing CVP, suggesting that falling sST2 paralleled successful treatment. In addition, there was a relationship between sST2 and fluid balance. Among patients randomized to liberal management, higher sST2 on day 0 was associated with significantly higher cumulative fluid balance from days 0 to 3, whereas among those receiving conservative fluid management, fluid balance was not significantly different, suggesting that conservative treatment may mitigate the association between sST2 concentration and fluid balance. At day 3, higher sST2 concentration was associated with significantly higher fluid balance among all groups. Although causality cannot be determined, it seems plausible that sST2 concentrations at day 3 are reflective of more positive fluid balance over days 0-3. Further evidence for this is provided by linear regression, showing a significant association between fluid balance and day 3 sST2 concentration, modeled as an outcome.
These data suggest that sST2 concentrations may describe a population of patients who are responsive to conservative fluid management, in that sST2 concentrations fall along with CVP, and are associated with fluid balance. It is difficult to elucidate whether high sST2 concentrations at day 3 were a result of inadequate attempts at conservative fluid management or whether these patients represent a subset of ARDS patients who were refractory to therapy. On a related note, as Liu et al (25) showed, liberal fluid management was associated with a greater prevalence of organ failure (specifically, AKI) in FACTT. Another study suggests that diuretic use was protective against mortality in this cohort (26) . These suggest that sST2 concentration might identify a population of patients who might benefit from increased fluid removal. This hypothesis could be tested in a clinical trial.
In addition to the prognostic information discussed, and existing data demonstrating utility for risk stratification in ischemic heart disease and HF (16, 27, 28) , our data suggest potential diagnostic utility for sST2. This is of interest because both ARDS and acutely decompensated HF involve respiratory failure and pulmonary edema and may be difficult to distinguish clinically (29, 30) . For this analysis, we selected HF patients from PRIDE with respiratory distress and radiographic evidence of pulmonary edema compatible with the diagnosis of ARDS and found that baseline sST2 values had high sensitivity and specificity for discriminating between study populations. This finding should be further developed to determine whether sST2 concentration may be used as a biomarker for diagnostic purposes.
Despite these findings, there are still important questions to be answered regarding the mechanistic role of sST2 in ARDS. To date, human studies have focused on the role of sST2 as a marker of myocardial strain. Given the associations found with fluid balance and clinical outcomes, it seems plausible that sST2 is elevated due to myocardial strain in patients with ARDS. Other studies in similar populations have also suggested a prognostic role for myocardial injury markers (6, 31) . However, it is not clear why patients with ARDS had markedly higher sST2 concentrations than HF patients; in patients with end-stage HF syndromes, sST2 concentrations may be higher than the subjects in PRIDE, but still most often lower than most of the ARDS subjects from FACTT (J. Januzzi, personal observation). Other studies have also shown lower sST2 values in patients with other cardiac conditions than the concentrations seen in ARDS patients here (16, 17) . We note that there are numerous other studies suggesting a role for this molecule in inflammation, which may explain the high sST2 values we recorded in FACTT. In particular, studies have implicated the ST2/IL-33 pathway in the pathogenesis of asthma and other pulmonary inflammatory states. One study by Tajima et al (32) showed increased sST2 expression in a mouse model of bleomycin lung injury and in vitro preparations of human lung fibroblasts and alveolar epithelium that were subjected to inflammatory stimuli. Another human showed increased sST2 concentrations during exacerbations of pulmonary fibrosis (12) . Combined with our findings, it seems plausible that the combination of myocardial strain and inflammation seen in ARDS would result in markedly higher concentrations than myocardial strain alone. Further research is needed to determine what factors are associated with sST2 production in ARDS, whether this molecule acts as an important mediator in human ARDS, and whether this biomarker is specific for pulmonary inflammation.
We acknowledge that this study has some important limitations. First, conceptually, in order for a biomarker to add utility to clinical practice or scientific understanding, it should provide information that is not readily available through routine clinical measures (33) . For example, although baseline sST2 values here showed excellent discriminative ability for ARDS versus HF, the "gold standard" in this study is still routine clinical diagnosis. Another important caveat to these results is the high potential for unappreciated confounding in comparing FACTT and PRIDE patients. There were major differences in the design of these studies, and study results could vary considerably on that basis alone. Although we have hypothesized that the large difference in sST2 between groups is related to diagnosis, this relationship might be confounded by differences in patient characteristics, sampling time, need for mechanical ventilation, or other unmeasured variables. Because of the question of the difference between comparison groups, these results can only be viewed as preliminary and hypothesis-generating. Further studies accounting for confounders are necessary to determine whether sST2 can truly discriminate between conditions. If this biomarker offers specific information regarding pathophysiology that cannot be otherwise obtained, it could be a useful adjunct to clinical diagnosis or offer other insights into disease processes. In addition, sST2 may provide value in terms of overall prognosis as well as predicting or gauging response to fluid management strategies. However, these possibilities must be proven in studies that are designed with those goals in mind.
In addition, partly because we were limited by the available data and biospecimens and by the size of our article, we did not include detailed analyses of pathophysiologic factors such as subsequent organ failures (including serial organ failure scores or APACHE III scores after the first 24 hr), the relationship between biomarker levels and measures of cardiac function (such as right ventricular function), or the relationship between sST2 and other inflammatory or cardiac biomarkers such as ILs or cardiac troponins. As such, our article is limited in terms of understanding the contribution of such factors to characteristics of sST2 concentration in ARDS patients. Further study is required to better understand these issues.
CONCLUSIONS
Plasma sST2 concentrations in patients with ARDS are predictive of worse outcomes and are associated with fluid management variables such as fluid balance and response to fluid management strategy. When patients from the FACTT and PRIDE studies were compared, baseline sST2 concentrations also showed excellent ability to discriminate between these study populations, although these results should be viewed as hypothesis-generating, and future studies are needed to test this in conjunction with other standard clinical assessments that are used to distinguish HF from ARDS. Additional studies will be needed to further determine mechanistic factors associated with sST2 production and evaluate its clinical utility.
